Zoetis (NYSE:ZTS) Sets New 1-Year Low - Here's What Happened

Key Points

• 52-week low: Zoetis shares fell to a new 52-week low of $112.10 (last $112.81) on Tuesday, with about 3.21 million shares changing hands.
• Analyst mix: The consensus rating is "Hold" with an average price target of $151.75 (seven Buy, seven Hold, one Sell), while recent notable moves include Citigroup initiating coverage at Buy ($145) and UBS trimming its target to $130.
• Fundamentals and payouts: Zoetis beat quarterly estimates (EPS $1.48 vs. $1.40; revenue $2.39B, +3% y/y) and guided FY2026 to $7.00–$7.10 EPS; it also declared a $0.53 quarterly dividend (1.9% yield) and has roughly 92.8% institutional ownership.

Zoetis Inc. (NYSE:ZTS - Get Free Report) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $112.10 and last traded at $112.8090, with a volume of 3211457 shares. The stock had previously closed at $114.16.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ZTS shares. Citigroup started coverage on Zoetis in a report on Wednesday, April 15th. They issued a "buy" rating and a $145.00 price objective on the stock. Leerink Partners reiterated a "market perform" rating on shares of Zoetis in a report on Tuesday, March 10th. Bank of America lifted their price objective on Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a report on Friday, February 13th. BTIG Research reiterated a "buy" rating and issued a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Finally, UBS Group decreased their price objective on Zoetis from $136.00 to $130.00 and set a "neutral" rating on the stock in a report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zoetis currently has an average rating of "Hold" and an average price target of $151.75.

Zoetis Stock Performance

The company has a market cap of $47.45 billion, a PE ratio of 18.74, a P/E/G ratio of 1.76 and a beta of 0.87. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The business has a fifty day moving average of $119.93 and a 200-day moving average of $124.53.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the previous year, the business earned $1.40 EPS. Zoetis's revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts anticipate that Zoetis Inc. will post 7.01 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Monday, April 20th. Zoetis's payout ratio is currently 35.22%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company's stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares during the period. J. Stern & Co. LLP grew its holdings in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company's stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. State Street Corp grew its holdings in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company's stock worth $2,490,845,000 after acquiring an additional 149,382 shares during the period. Geode Capital Management LLC grew its holdings in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company's stock worth $1,420,294,000 after acquiring an additional 189,235 shares during the period. Finally, Norges Bank purchased a new position in shares of Zoetis during the 4th quarter worth approximately $734,425,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.